New cocktail of drugs shows promise for tough bile duct cancer
NCT ID NCT07432568
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors. The trial will enroll 30 participants and measure how many respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal irinotecan, 5-fluorouracil, leucovorin, lenvatinib, and a PD-1 inhibitor
What this could lead to
If successful, this could offer a new first-line treatment option for people with advanced bile duct cancer, potentially shrinking tumors and extending survival.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet proven to be better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.